Investor Relations

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

CR-000172

News Release

 View printer-friendly version

Charles River Laboratories Third Quarter 2000 Earnings Conference Call Scheduled

WILMINGTON, Mass.--(BW HealthWire)--Oct. 23, 2000--Charles River Laboratories International, Inc. (NYSE:CRL) and Charles River Laboratories, Inc. (together "Charles River") have scheduled a conference call to discuss third quarter 2000 financial results.

The call is scheduled to take place on November 2, 2000 at 11:00 a.m. Eastern Standard Time. Charles River will release third quarter 2000 earnings after the market closes on Wednesday, November 1, 2000.

Investors will have the opportunity to listen to the conference call over the Internet through the company's website at http://www.criver.com. To listen to the live broadcast, please go to the website anytime before the call but at least fifteen minutes early, to register, download, and install any necessary audio software.

For those who cannot listen to the live broadcast, a replay will be available on the website shortly after the call and will remain available for ninety days.

Charles River, based in Wilmington, Massachusetts, is a leading provider of critical research tools and integrated support services that enable innovative and efficient drug discovery and development. The Company is the global leader in providing the animal research models required in research and development for new drugs, devices and therapies.

The Company also offers a broad portfolio of biomedical products and services that enable customers to reduce costs, increase speed and enhance productivity and effectiveness in drug discovery and development.

Charles River's customer base spans over 50 countries, and includes all of the major pharmaceutical and biotechnology companies, as well as many leading hospitals and academic institutions. The Company operates 53 facilities in 15 countries worldwide.

--30--NR/ph*

CONTACT: Charles River Laboratories International, Inc.
Dennis R. Shaughnessy or Marcia Gookin
Investor Relations
978-658-6000 ext. 1329


Featured Report

2018 Annual Report (PDF)

Investor Hotline

877-567-6CRL (6275)